Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid

Xiang,Lili; Zhou,Jiahe; Gu,Weiying; Wang,Rong; Wei,Jiang; Qiu,Guoqiang; Cen,Jiannong; Xie,Xiaobao; Chen,Zixing

doi:10.3892/ol.2015.4052

Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid

Authors:
- Lili Xiang
- Jiahe Zhou
- Weiying Gu
- Rong Wang
- Jiang Wei
- Guoqiang Qiu
- Jiannong Cen
- Xiaobao Xie
- Zixing Chen
View Affiliations

Affiliations: Department of Hematology, The Center Hospital of Xuzhou, Xuzhou, Jiangsu, P.R. China, Department of Urology, The Center Hospital of Xuzhou, Xuzhou, Jiangsu, P.R. China, Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, P.R. China, Laboratory of China and United States Cooperation, The First People's Hospital of Changzhou, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, P.R. China, Comprehensive Laboratory, The First People's Hospital of Changzhou, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, P.R. China, Hematology Laboratory, The First People's Hospital of Changzhou, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, P.R. China, Jiangsu Institute of Hematology, The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, P.R. China
Published online on: December 23, 2015 https://doi.org/10.3892/ol.2015.4052
Pages: 1521-1526

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of 5-aza-2'-deoxycytidine (decitabine; DAC) and all-trans retinoic acid (ATRA) on Wilms' tumor 1 (WT1) in acute myeloid leukemia (AML) in vitro. The methylation status of the WT1 promoter was analyzed using methylation‑specific polymerase chain reaction (MSP). The expression level of WT1 was detected by reverse transcription‑quantitative polymerase chain reaction. The effect of DAC and ATRA on cell differentiation was evaluated by flow cytometry. The WT1 gene was methylated in U937 cells, but unmethylated in SHI‑1 and K562 cells; the U937 cells did not express the WT1 gene, but the SHI‑1 and K562 cells highly expressed the WT1 gene. DAC and ATRA, alone or in combination, exhibited no effect on the expression level of WT1 in the U937 cells and on the differentiation of the K562 cells. The combined treatment of DAC and ATRA markedly decreased the WT1 expression levels of the SHI‑1 and K562 cells, and induced the differentiation of the SHI‑1 and U937 cells. In the SHI‑1 cells, WT1 expression changed inversely to the dynamic changes of cluster of differentiation 11b‑positive rates. In conclusion, the combined treatment of DAC and ATRA has clinical therapeutic potential in acute monocytic leukemia patients with high WT1 expression and a poor response to standard induction chemotherapy.

View Figures

View References

1	Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D and Jaenisch R: WT-1 is required for early kidney development. Cell. 74:679–691. 1993. View Article : Google Scholar : PubMed/NCBI
2	Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J and Housman D: The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 346:194–197. 1990. View Article : Google Scholar : PubMed/NCBI
3	Yang L, Han Y, Saiz Suarez F and Minden MD: A tumor suppressor and oncogene: The WT1 story. Leukemia. 21:868–876. 2007.PubMed/NCBI
4	Nakatsuka S, Oji Y, Horiuchi T, et al: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 19:804–814. 2006.PubMed/NCBI
5	Morrison AA, Viney RL and Ladomery MR: The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta. 1785:55–62. 2008.PubMed/NCBI
6	Im HJ, Kong G and Lee H: Expression of Wilms tumor gene (WT1) in children with acute leukemia. Pediatr Hematol Oncol. 16:109–118. 1999. View Article : Google Scholar : PubMed/NCBI
7	Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, et al: The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 13:393–399. 1999. View Article : Google Scholar : PubMed/NCBI
8	Sugiyama H: Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma. 30:55–61. 1998.PubMed/NCBI
9	Trka J, Kalinová M, Hrusák O, Zuna J, Krejcí O, Madzo J, Sedlácek P, Vávra V, Michalová K, Jarosová M, et al: Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia. 16:1381–1389. 2002. View Article : Google Scholar : PubMed/NCBI
10	Barragan E, Cervera J, Bolufer P, Ballester S, Martín G, Fernández P, Collado R, Sayas MJ and Sanz MA: Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 89:926–933. 2004.PubMed/NCBI
11	Haralambieva E, Banham AH, Bastard C, Delsol G, Gaulard P, Ott G, Pileri S, Fletcher JA and Mason DY: Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples. Br J Haematol. 121:49–56. 2003. View Article : Google Scholar : PubMed/NCBI
12	Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, et al: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 101:1698–1704. 2003. View Article : Google Scholar : PubMed/NCBI
13	Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Lo Coco F and Saglio G: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 16:2115–2121. 2002. View Article : Google Scholar : PubMed/NCBI
14	Gu W, Chen Z, Hu S, Shen H, Qiu G and Cao X: Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. Haematologica. 90:403–405. 2005.PubMed/NCBI
15	Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
16	Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT and Kantarjian H: Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 27:3842–3848. 2009. View Article : Google Scholar : PubMed/NCBI
17	Voso MT, Santini V, Finelli C, et al: Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res. 15:5002–5007. 2009. View Article : Google Scholar : PubMed/NCBI
18	Christman JK: 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene. 21:5483–5495. 2002. View Article : Google Scholar : PubMed/NCBI
19	Cashen AF, Schiller GJ, O'Donnell MR and DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 28:556–561. 2010. View Article : Google Scholar : PubMed/NCBI
20	Donner A: Leukemia: PHFriends with RAR. Nat Chem Biol. 9:291. 2013. View Article : Google Scholar
21	Yang J, Ikezoe T, Nishioka C and Yokoyama A: Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells. Apoptosis. 18:1403–1415. 2013. View Article : Google Scholar : PubMed/NCBI
22	Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon MY, Goldman JM and Stauss HJ: Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 95:2198–2203. 2000.PubMed/NCBI
23	Baird PN and Simmons PJ: Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol. 25:312–320. 1997.PubMed/NCBI
24	Zhao Y, Chen ZX, Hu SY, Cen JN and Gu WY: Study on DNA methylation status of WT1 gene in its promoter region in hematologic malignancy cell lines. Zhonghua Xue Ye Xue Za Zhi. 26:517–520. 2005.(In Chinese). PubMed/NCBI
25	Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH Jr, Lo Coco F, Pelicci PG and Nervi C: Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene. 24:1820–1830. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lubbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, et al: A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 97:393–401. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xiang L, Dong W, Wang R, Wei J, Qiu G, Cen J, Chen Z, Zheng X, Hu S, Xie X, et al: All trans retinoic acid enhances the effect of 5 aza 2′ deoxycytidine on p16INK4a demethylation, and the two drugs synergistically activate retinoic acid receptor β gene expression in the human erythroleukemia K562 cell line. Oncol Lett. 8:117–122. 2014.PubMed/NCBI
28	Sugiyama H: Wilms' tumor gene WT1: Its oncogenic function and clinical application. Int J Hematol. 73:177–187. 2001. View Article : Google Scholar : PubMed/NCBI
29	Scharnhorst V, van der Eb AJ and Jochemsen AG: WT1 proteins: Functions in growth and differentiation. Gene. 273:141–161. 2001. View Article : Google Scholar : PubMed/NCBI
30	Ariyaratana S and Loeb DM: The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 9:1–17. 2007. View Article : Google Scholar : PubMed/NCBI
31	Rosenfeld C, Cheever MA and Gaiger A: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: Therapeutic potential of WT1 targeted therapies. Leukemia. 17:1301–1312. 2003. View Article : Google Scholar : PubMed/NCBI
32	Gu WY, Chen ZX, Cao XS, Hu SY, Zhu J, Wang ZL, Yan F, Wang W, Cen JN, Shen HL and Qian J: Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR. Zhonghua Xue Ye Xue Za Zhi. 25:728–731. 2004.(In Chinese). PubMed/NCBI
33	Sekiya M, Adachi M, Hinoda Y, Imai K and Yachi A: Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood. 83:1876–1882. 1994.PubMed/NCBI
34	Wang L, Chen ZX, Fu JX, Cen JN and Wang W: Change of WT1 gene expression during induction of differentiation of NB4 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 9:128–131. 2001.(In Chinese). PubMed/NCBI
35	Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T and Schnittger S: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 19:1416–1423. 2005. View Article : Google Scholar : PubMed/NCBI